Implications of corticotropin releasing factor in targeted anticancer therapy

Journal of Pharmacy Practice

Volumn 23, Issue 2, 2010, Pages 86-90

  Kim, Byung Jin ^a   Jones, Harlan P ^a  

^a UNIVERSITY OF NORTH TEXAS   (United States)

Author keywords

Cancer; Chemokine; Corticotropin releasing factor; Cytokine; Drug therapy; Immune

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

CARCINOGENESIS; HUMAN; REVIEW; TUMOR IMMUNOLOGY;

EID: 77953680569     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190009360023     Document Type: Review

References (40)

1. Pyter LM, Pineros V., Galang JA, et al. Peripheral tumors induce depressive-like behaviors and cytokine production and alter hypothalamic- pituitary-adrenal axis regulation. Proc Natl Acad Sci U S A. 2009 ; 106 (22). 9069-9074.
2. Fitzgerald PJ Is norepinephrine an etiological factor in some types of cancer? Int J Cancer. 2009 ; 124 (2). 257-263.
3. Jordan VC A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention. Cancer Res. 2009 ; 69 (4). 1243-1254.
4. Feige JJ Angiogenesis in adrenocortical physiology and tumor development. Ann Endocrinol (Paris). 2009 ; 70 (3). 153-155.
5. Zänker KS The neuro-neoplastic synapse: does it exist? Prog Exp Tumor Res. 2007 ; 39: 154-161.
6. Crofford LJ, Sano H., Karalis K., et al. Local secretion of corticotropin-releasing hormone in the joints of Lewis rats with inflammatory arthritis. J Clin Invest. 1992 ; 90 (6). 2555-2564.
7. Coste SC, Murray SE, Stenzel-Poore MP Animal models of CRH excess and CRH receptor deficiency display altered adaptations to stress. Peptides. 2001 ; 22 (5). 733-741.
8. Jessop DS, Harbuz MS, Lightman SL CRH in chronic inflammatory stress. Peptides. 2001 ; 22 (5). 803-807.
9. Audhya T., Jain R., Hollander CS Receptor-mediated immunomodulation by corticotropin-releasing factor. Cell Immunol. 1991 ; 134 (1). 77-84.
10. Jain R., Zwickler D., Hollander CS, et al. Corticotropin-releasing factor modulates the immune response to stress in the rat. Endocrinology. 1991 ; 128 (3). 1329-1336.
11. Boorse GC, Denver RJ Widespread tissue distribution and diverse functions of corticotropin-releasing factor and related peptides. Gen Comp Endocrinol. 2006 ; 146 (1). 9-18.
12. Lawrence KM, Latchman DS The Urocortins: mechanisms of cardioprotection and therapeutic potential. Mini Rev Med Chem. 2006 ; 10: 1119-1126.
13. Saito-Nakaya K., Hasegawa R., Nagura Y., et al. Corticotropin-releasing hormone receptor 1 antagonist blocks colonic hypersensitivity induced by a combination of inflammation and repetitive colorectal distension. Neurogastroenterol Motil. 2008 ; 20 (10). 1147-1156.
14. Ralph JA, Zocco D., Bresnihan B., et al. A role for type 1alpha corticotropin-releasing hormone receptors in mediating local changes in chronically inflamed tissue. Am J Pathol. 2007 ; 170 (3). 1121-1133.
15. Fazal N., Slominski A., Choudhry MA, et al. Effect of CRF and related peptides on calcium signaling in human and rodent melanoma cells. FEBS Lett. 1998 ; 435 (2-3). 187-190.
16. Reubi JC, Waser B., Vale W., et al. Expression of CRF1 and CRF2 receptors in human cancers. J Clin Endocrinol Metab. 2003 ; 88 (7). 3312-3320.
17. Tjuvajev J., Kolesnikov Y., Joshi R., et al. Anti-neoplastic properties of human corticotropin releasing factor: involvement of the nitric oxide pathway. In Vivo. 1998 ; 12 (1). 1-10.
18. Graziani G., Tentori L., Muzi A., et al. Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. Mol Cell Endocrinol. 2007 ; 264 (1-2). 44-49.
19. Carlson KW, Nawy SS, Wei ET, et al. Inhibition of mouse melanoma cell proliferation by corticotropin-releasing hormone and its analogs. Anticancer Res. 2001 ; 21 (2A). 1173-1179.
20. Androulidaki A., Dermitzaki E., Venihaki M., et al. Corticotropin releasing factor promotes breast cancer cell motility and invasiveness. Mol Cancer. 2009 ; 8: 30.
21. Graziani G., Ferrandina G., Pozzoli G., et al. Corticotropin-releasing hormone receptor-1 in human endometrial cancer. Oncol Rep. 2006 ; 15 (2). 375-379.
22. Oble DA, Loewe R., Yu P., et al. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun. 2009 ; 9: 3.
23. Rollins BJ Release the hounds! A chemokine elicits monocytes from bone marrow. Nat Immunol. 2006 ; 7 (3). 230-232.
24. Rollins BJ Inflammatory chemokines in cancer growth and progression. Eur J Cancer. 2006 ; 42 (6). 760-767.
25. Quesnel B. Tumor dormancy and immunoescape. APMIS. 2008 ; 116 (7-8). 685-694.
26. Huang HC, Huang CY, Lin-Shiau SY, et al. Ursolic acid inhibits IL-1beta or TNF-alpha-induced C6 glioma invasion through suppressing the association ZIP/p62 with PKC-zeta and downregulating the MMP-9 expression. Mol Carcinog. 2009 ; 48 (6). 517-531.
27. Koontongkaew S., Amornphimoltham P., Yapong B. Tumor-stroma interactions influence cytokine expression and matrix metalloproteinase activities in paired primary and metastatic head and neck cancer cells Cell Biol Int. 2009 ; 33 (2). 165-173.
28. Romero JM, Sáenz-López P., Cózar JM, et al. A polymorphism in the interleukin-10 promoter affects the course of disease in patients with clear-cell renal carcinoma. Hum Immunol. 2009 ; 70 (1). 60-64.
29. Fong YC, Hsu SF, Wu CL, et al. Transforming growth factor-beta1 increases cell migration and beta1 integrin up-regulation in human lung cancer cells. Lung Cancer. 2009 ; 64 (1). 13-21.
30. Saudemont A., Jouy N., Hetuin D., et al. NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTLmediated lysis and can express B7-H1 that stimulates T cells. Blood. 2005 ; 105 (6). 2428-2435.
31. Quesnel B. Tumor dormancy: is adaptative immunity a key player? Med Sci (Paris). 2008 ; 24 (6-7). 575-576.
32. Zafiropoulos A., Crikas N., Passam AM, et al. Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J Med Genet. 2004 ; 41 (5). e59.
33. Suarez-Cuervo C., Harris KW, Kallman L. Tumor necrosis factor-alpha induces interleukin-6 production via extracellular-regulated kinase 1 activation in breast cancer cells. Breast Cancer Res Treat. 2003 ; 80 (1). 71-78.
34. Zou W., Machelon V., Coulomb-LHermin A., et al. Stromalderived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med. 2001 ; 7 (12). 1339-1346.
35. Upadhyay R., Jain M., Kumar S., Ghoshal UC, Mittal B. Association of interleukin-6 (-174G>C) promoter polymorphism with risk of squamous cell esophageal cancer and tumor location: an exploratory study. Clin Immunol. 2008 ; 128 (2). 199-204.
36. Huang HC, Huang CY, Lin-Shiau SY, Lin JK Ursolic acid inhibits IL-1beta or TNF-alpha-induced C6 gliomo invasion through suppressing the association ZIP/p62 with PKC-zeta and downregulating the MMP-9 expression Mol Carcinog. 2009 ; 48 (6). 517-531.
37. Koontongkaew S., Amornphimoltham P., Yapong B. Tumor-stroma interactions influence cytokine expression and matrix metalloproteinase activities in paired primary and metastatic head and neck cancer cells Cell Biol Int. 2009 ; 33 (2). 165-173.
38. Romero JM, Sáenz-López P., Cózar JM, et al. A polymorphism in the interleukin-10 promoter affects the course of disease in patients with clear-cell renal carcinoma. Hum Immunol. 2009 ; 70 (1). 60-64.
39. Fong YC, Hsu SF, Wu CL, et al. Transforming growth factor-beta1 increases cell migration and beta1 integrin up-regulation in human lung cancer cells. Lung Cancer. 2009 ; 64 (1). 13-21.
40. Yuan Q., Li PD, Li BH, et al. Differential IL-4/Stat6 activities correlate with differential expression of regulatory genes SOCS-1, SHP-1, and PP2A in colon cancer cells. J Cancer Res Clin Oncol. 2009 ; 135 (1). 131-140.